(5-cyano-2-methoxypyridin-3-yl)boronic acid | 1231231-15-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (5-cyano-2-methoxypyridin-3-yl)boronic acid
• 英文别名: 2-methoxy-5-cyanopyridine-3-boronic acid
• CAS: 1231231-15-4
• 化学式: C₇H₇BN₂O₃
• 分子量: 177.955
• InChiKey: IVQRJPCEJUPSMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.36
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  86.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (5-cyano-2-methoxypyridin-3-yl)boronic acid 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 21.0h， 生成 tert-butyl (2-((4-(5-cyano-2-methoxypyridin-3-yl)thiophen-2-yl)amino)-1-(4-(ethylsulfonyl)phenyl)-2-oxoethyl)carbamate
  参考文献：
  名称：

  Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design

  摘要：

  Retinoic acid receptor related orphan receptor gamma t (ROR gamma t), has been identified as the master regulator of T(H)17-cell function and development, making it an attractive target for the treatment of autoimmune diseases by a small-molecule approach. Herein, we describe our investigations on a series of 4-aryl-thienyl acetamides, which were guided by insights from X-ray cocrystal structures. Efforts in targeting the cofactor-recruitment site from the 4-aryl group on the thiophene led to a series of potent binders with nanomolar activity in a primary human-T(H)17-cell assay. The observation of a DMSO molecule binding in a subpocket outside the LBD inspired the introduction of an acetamide into the benzylic position of these compounds. Hereby, a hydrogen-bond interaction of the introduced acetamide oxygen with the backbone amide of Glu379 was established. This greatly enhanced the cellular activity of previously weakly cell-active compounds. The best compounds combined potent inhibition of IL-17 release with favorable PK in rodents, with compound 32 representing a promising starting point for future investigations.

  DOI：

  10.1021/acs.jmedchem.8b00783

文献信息

• Compounds with medicinal effects due to interaction with the glucocorticoid receptor
  申请人：Hamilton Morton Niall

  公开号：US20070149577A1

  公开（公告）日：2007-06-28

  The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R 1 is hydrogen, halogen, CN or (1C-4C)alkyl; R 2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R 3 and R 5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R 4 is hydrogen, halogen, optionally halogenated (1C-4C)alkoxy or optionally halogenated aryl(1C-4C)alkoxy; R 6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1C-4C)alkyl, or R 6 is optionally halogenated (1C-4C)alkyl; each R 7 independently is hydrogen, halogen, optionally halogenated (1C-4C)alkyl or optionally halogenated (1C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.

  该发明提供了具有以下结构的化合物，符合以下式I的结构：其中：X是碳或氮原子；Ar是苯基或杂环芳香环；R1是氢、卤素、CN或(1C-4C)烷基；R2是氢、卤素或可选氟化的(1C-3C)烷氧基；R3和R5分别是氢、可选卤代的(1C-4C)烷基、可选卤代的(1C-4C)烷氧基、可选卤代的芳基(1C-4C)烷氧基、可选卤代的(1C-4C)烯基或羟甲基；R4是氢、卤素、可选卤代的(1C-4C)烷氧基或可选卤代的芳基(1C-4C)烷氧基；R6是氢、苄基，可选用一个或多个卤素或(1C-4C)烷基取代，或R6是可选卤代的(1C-4C)烷基；每个R7独立地是氢、卤素、可选卤代的(1C-4C)烷基或可选卤代的(1C-4C)烷氧基，以及其药用合适的酸盐，用作糖皮质激素受体调节剂，特别用于治疗中枢神经系统疾病。
• WO2007/56191
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist
  作者：Angus R. Brown、Michael Bosies、Helen Cameron、John Clark、Angela Cowley、Mark Craighead、Moira A. Elmore、Alistair Firth、Richard Goodwin、Susan Goutcher、Emma Grant、Morag Grassie、Simon J.A. Grove、Niall M. Hamilton、Hannah Hampson、Alison Hillier、Koc-Kan Ho、Michael Kiczun、Celia Kingsbury、Steven G. Kultgen、Peter T.A. Littlewood、Scott J. Lusher、Susan MacDonald、Lorraine McIntosh、Theresa McIntyre、Ashvin Mistry、J. Richard Morphy、Olaf Nimz、Michael Ohlmeyer、Jack Pick、Zoran Rankovic、Brad Sherborne、Alasdair Smith、Michael Speake、Gayle Spinks、Fiona Thomson、Lynn Watson、Mark Weston

  DOI：10.1016/j.bmcl.2010.11.054

  日期：2011.1

  High-throughput screening of 3.87 million compounds delivered a novel series of non-steroidal GR antagonists. Subsequent rounds of optimisation allowed progression from a non-selective ligand with a poor ADMET profile to an orally bioavailable, selective, stable, glucocorticoid receptor antagonist. (C) 2010 Published by Elsevier Ltd.